Identification of melanoma antigens that are immunogenic in humans and expressed in vivo

Journal of the National Cancer Institute

Volumn 90, Issue 2, 1998, Pages 146-149

  Applebaum, Jason ^a   Reynolds, Sandra ^a   Knispel, Jeff ^a   Oratz, Ruth ^a   Shapiro, Richard ^a   Bystryn, Jean Claude ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; MELANOMA ANTIGEN; MELANOMA VACCINE; TUMOR ANTIGEN; TUMOR VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; CANCER IMMUNOLOGY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOBLOTTING; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; SKIN TUMOR;

EID: 0032554053     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.2.146     Document Type: Article

References (17)

1. Bystryn JC, Shapiro RL, Oratz R. Cancer vaccines: clinical applications: partially purified tumor antigen vaccines. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. 2nd ed. Philadelphia: Lippincott, 1995:668-79.
2. Lloyd K. Tumor antigens. Ann N Y Acad Sci 1993;690:50-9.
3. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179: 921-30.
4. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
5. Oka T, Kikumoto Y, Itakura K, Morton DL, Irie RF. Human monoclonal antibody identified an immunoreactive tetrapeptide sequence (Lys-Tyr-Gln-Ile) in Mr 43,000 protein of human melanoma. Cancer Res 1994;54:3511-5.
6. Hersey P, Werkman H, Edwards AE. Western blot analysis of serological responses following immunization with vaccinia viral lysates of melanoma cells. Int J Cancer 1990;46:612-7.
7. Bystryn JC, Henn M, Li J, Shroba S. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res 1992;52:5948-53.
8. Livingston PO. Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann N Y Acad Sci 1993;690: 204-13.
9. Berthier-Vergnes O, Portoukalian J, Leftheriotis E, Dore JF. Induction of IgG antibodies directed to a Mr 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res 1994;54: 2433-9.
10. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1985;35:607-12.
11. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relation between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-64.
12. Bystryn JC, Jacobsen S, Harris M, Roses D, Speyer J, Levin M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J Biol Response Mod 1986;5: 221-4.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacterio-phage T4. Nature 1970;2127:680-5.
14. Livingston PO, Kaelin K, Pinsky CM, Oettgen HF, Old LJ. The serological response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer 1985;56: 2194-200.
15. Helling F, Adluri S, Calves M, Koganty RR, Oettgen HF, Livington PO. Increased immunogenicity of GM2 conjugated with KLH and used with adjuvant in patients with melanoma. Proc Am Assoc Cancer Res 1993;34:491.
16. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179: 1005-9.
17. Wolfel T, Van Pel A, Brichard V, Schneider J, Selliger B, Meyer zum Buschenfelde KH, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.